Overview

Efficacy and Safety Study of the Fixed-dose Combination of Olmesartan + Indapamide When Compared to the Isolated Drugs in the Treatment of Hypertension.

Status:
Not yet recruiting

Trial end date:
2023-06-01

Target enrollment:

Participant gender:

Summary

Phase III clinical trial, multicenter of non-inferiority, randomized, single-blind evaluation of fixed-dose combination of olmesartan + indapamide compared to the isolated drugs in the treatment of hypertension.

Phase:

Phase 3

Details

Lead Sponsor:

Brainfarma Industria Química e Farmacêutica S/A

Treatments:

Indapamide
Olmesartan
Olmesartan Medoxomil